Literature DB >> 28617077

Factors affecting immune responses to the influenza vaccine.

Maria R Castrucci1.   

Abstract

Annual administration of the seasonal influenza vaccine is strongly recommended to reduce the burden of disease, particularly for persons at the highest risk for the viral infection. Even during years when there is a good match between the vaccine and circulating strains, host-related factors such as age, preexisting immunity, genetic polymorphisms, and the presence of chronic underlying conditions may compromise influenza vaccine responsiveness. The application of new methodologies and large-scale profiling technologies are improving the ability to measure vaccine immunogenicity and our understanding of the immune mechanisms by which vaccines induce protective immunity. This review attempts to summarize the general concepts of how host factors can contribute to the heterogeneity of immune responses induced by influenza vaccines.

Entities:  

Keywords:  aging; genetic polymorphism; immune response; immunocompromised; influenza vaccine

Mesh:

Substances:

Year:  2017        PMID: 28617077      PMCID: PMC5861809          DOI: 10.1080/21645515.2017.1338547

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  125 in total

1.  Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.

Authors:  Adrian J Reber; Jin Hyang Kim; Renata Biber; H Keipp Talbot; Laura A Coleman; Tatiana Chirkova; F Liaini Gross; Evelene Steward-Clark; Weiping Cao; Stacie Jefferson; Vic Veguilla; Eric Gillis; Jennifer Meece; Yaohui Bai; Heather Tatum; Kathy Hancock; James Stevens; Sarah Spencer; Jufu Chen; Paul Gargiullo; Elise Braun; Marie R Griffin; Maria Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  Open Forum Infect Dis       Date:  2015-04-15       Impact factor: 3.835

2.  Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.

Authors:  Helder I Nakaya; Thomas Hagan; Sai S Duraisingham; Eva K Lee; Marcin Kwissa; Nadine Rouphael; Daniela Frasca; Merril Gersten; Aneesh K Mehta; Renaud Gaujoux; Gui-Mei Li; Shakti Gupta; Rafi Ahmed; Mark J Mulligan; Shai Shen-Orr; Bonnie B Blomberg; Shankar Subramaniam; Bali Pulendran
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

Review 3.  Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.

Authors:  G A Poland; I G Ovsyannikova; R M Jacobson; D I Smith
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

4.  On the relationship between mean antibody level, seroprotection and clinical protection from influenza.

Authors:  Jozef J P Nauta; Walter E P Beyer; Albert D M E Osterhaus
Journal:  Biologicals       Date:  2009-03-05       Impact factor: 1.856

5.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.

Authors:  David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

6.  Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine.

Authors:  Hye-Lim Park; Seung-Hyun Shim; Eun-Young Lee; Whajung Cho; Sooho Park; Hyun-Jung Jeon; Sun-Young Ahn; Hun Kim; Jae-Hwan Nam
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

7.  Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.

Authors:  Mark G Thompson; Allison Naleway; Alicia M Fry; Sarah Ball; Sarah M Spencer; Sue Reynolds; Sam Bozeman; Min Levine; Jacqueline M Katz; Manjusha Gaglani
Journal:  Vaccine       Date:  2016-02-10       Impact factor: 3.641

8.  Antibody landscapes after influenza virus infection or vaccination.

Authors:  J M Fonville; S H Wilks; S L James; A Fox; M Ventresca; M Aban; L Xue; T C Jones; N M H Le; Q T Pham; N D Tran; Y Wong; A Mosterin; L C Katzelnick; D Labonte; T T Le; G van der Net; E Skepner; C A Russell; T D Kaplan; G F Rimmelzwaan; N Masurel; J C de Jong; A Palache; W E P Beyer; Q M Le; T H Nguyen; H F L Wertheim; A C Hurt; A D M E Osterhaus; I G Barr; R A M Fouchier; P W Horby; D J Smith
Journal:  Science       Date:  2014-11-21       Impact factor: 47.728

9.  Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination.

Authors:  Alastair J Moss; Fiona P Gaughran; Aliyye Karasu; Anthony S Gilbert; Alex J Mann; Colin M Gelder; John S Oxford; Henry A Stephens; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

10.  Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis.

Authors:  Zhengfa Liao; Hao Tang; Xiaojia Xu; Yaping Liang; Yongzhen Xiong; Jindong Ni
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

View more
  27 in total

1.  The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia.

Authors:  April Sykes; Elsie Gerhardt; Li Tang; Elisabeth E Adderson
Journal:  J Pediatr       Date:  2017-12       Impact factor: 4.406

2.  100 years since the 1918 influenza pandemic.

Authors:  Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2018-03-04       Impact factor: 3.452

3.  Influence function methods to assess the effectiveness of influenza vaccine with survey data.

Authors:  Mingmei Tian; Jihnhee Yu; Denise F Lillvis; Albert Vexler
Journal:  Health Serv Res       Date:  2021-10-22       Impact factor: 3.402

Review 4.  Age-related factors that affect B cell responses to vaccination in mice and humans.

Authors:  Daniela Frasca; Bonnie B Blomberg; Denisse Garcia; Spencer R Keilich; Laura Haynes
Journal:  Immunol Rev       Date:  2020-06-02       Impact factor: 12.988

Review 5.  Factors influencing the immunogenicity of influenza vaccines.

Authors:  Simin Wen; Zhengyu Wu; Shuyi Zhong; Mao Li; Yuelong Shu
Journal:  Hum Vaccin Immunother       Date:  2021-03-11       Impact factor: 3.452

6.  Global Influenza Hospital-based Surveillance Network (GIHSN): results of surveillance of influenza and other respiratory viruses in hospitalised patients in Brazil, 2015.

Authors:  Sonia M Raboni; Fernanda E A Moura; Braulia C Caetano; Valéria M Avanzi; Luciane A Pereira; Meri B Nogueira; Luine R Vidal; Isabel C F Tavares; Florence K Pradel; Valentina S Picot; Joan Puig-Barbera; Marilda M Siqueira
Journal:  BMJ Open       Date:  2018-02-15       Impact factor: 2.692

7.  Roads to advanced vaccines: influenza case study.

Authors:  Peggy Riese; Carlos A Guzmán
Journal:  Microb Biotechnol       Date:  2017-08-15       Impact factor: 5.813

8.  Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge.

Authors:  Breanna Hodgins; Stephane Pillet; Nathalie Landry; Brian J Ward
Journal:  Immun Ageing       Date:  2019-11-04       Impact factor: 6.400

9.  Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.

Authors:  Maria Ganczak; Paulina Dubiel; Marzena Drozd-Dąbrowska; Ewelina Hallmann-Szelińska; Karol Szymański; Lidia B Brydak
Journal:  Int J Environ Res Public Health       Date:  2019-11-14       Impact factor: 3.390

10.  Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).

Authors:  Jeffrey Baker; Stanley L Block; Balpreet Matharu; Laura Burleigh Macutkiewicz; Steffen Wildum; Sophie Dimonaco; Neil Collinson; Barry Clinch; Pedro A Piedra
Journal:  Pediatr Infect Dis J       Date:  2020-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.